Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Allergan |
---|---|
Information provided by: | Allergan |
ClinicalTrials.gov Identifier: | NCT00652483 |
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
Condition | Intervention | Phase |
---|---|---|
Glaucoma Ocular Hypertension |
Drug: Brimonidine ophthalmic solution 0.1% Drug: Brimonidine ophthalmic solution 0.2% |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
Enrollment: | 433 |
Study Start Date: | May 2003 |
Study Completion Date: | September 2004 |
Primary Completion Date: | December 2003 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Brimonidine ophthalmic solution 0.1%
|
Drug: Brimonidine ophthalmic solution 0.1%
1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
|
2: Active Comparator
Brimonidine ophthalmic solution 0.2%
|
Drug: Brimonidine ophthalmic solution 0.2%
1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Allergan ( Therapeutic Area Head ) |
Study ID Numbers: | 190342-021 |
Study First Received: | April 1, 2008 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00652483 |
Health Authority: | United States: Food and Drug Administration |
Glaucoma Eye Diseases Vascular Diseases |
Brimonidine Hypertension Ocular Hypertension |
Neurotransmitter Agents Adrenergic alpha-Agonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses Physiological Effects of Drugs |
Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Adrenergic Agonists |